A Huxiu AI reprint of a Shenlan Guan article reports that this autumn the AI drug discovery field's attention is shifting from molecule generation toward digital twins and virtual cells, with practitioners saying the direction has been repeatedly raised since summer and that many AIDD companies now describe plans to move into virtual cells. The report says that in early October Mark Zuckerberg's Biohub expanded its virtual biology program to $1.8 billion, working with the US Department of Energy, NIH and Google DeepMind to build public data infrastructure for virtual cell models, and that nearly 10 related funding deals have appeared in China since April 2026. It also lists bottlenecks: calibrated dynamic time-series quantitative single-cell data is scarce, single-cell sequencing yields only snapshots, and models struggle to pass wet-lab validation of extrapolation and drug-perturbation prediction; virtual clinical trials and digital-twin diagnostics also lack mature regulatory and review standards, and the business model remains unclear.